Dr Howard Weiner from the Harvard Medical School and Tiziana Life Sciences PLC’s (LON:TILS) (NASDAQ:TLSA) scientific advisory board chairman speaks to Proactive’s Andrew Scott following the news they’ve completed the clinical trial of its nasally administered Foralumab for the treatment…
![Why Q Sciences Why Q Sciences](https://www.vitaminrush.com/wp-content/uploads/2021/01/1609883644_maxresdefault-1170x508.jpg)